Driehaus Capital Management LLC Chinook Therapeutics, Inc. Transaction History

Driehaus Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $12.1 Million - $25 Million	-648,283 Reduced 85.83%	107,053 $4.11 Million
Q1 2023 May 15, 2023	SELL	$21.53 - $26.8 $373,846 - $465,355	-17,364 Reduced 2.25%	755,336 $17.5 Million
Q4 2022 Feb 14, 2023	SELL	$18.63 - $27.35 $2.03 Million - $2.98 Million	-108,984 Reduced 12.36%	772,700 $20.2 Million
Q3 2022 Nov 14, 2022	BUY	$17.51 - $23.37 $6.82 Million - $9.1 Million	389,381 Added 79.09%	881,684 $17.3 Million
Q2 2022 Aug 15, 2022	BUY	$12.59 - $18.8 $6.2 Million - $9.26 Million	492,303 New	492,303 $8.61 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Driehaus Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Driehaus Capital Management LLC with notifications on news.